Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection
- PMID: 12111421
- DOI: 10.1007/s00705-002-0811-9
Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection
Abstract
Monkeys that have been vaccinated with nef-deleted SHIVs were either fully or partially protected against challenge with acute pathogenic SHIV-89.6 P. Viruses isolated from these vaccinated monkeys were all found to be the 89.6 P challenge virus using PCR amplification and restriction enzyme analysis of the env region of the viruses. Analysis of the 3'-end of the env region and 5'-half of the nef region using a heteroduplex mobility assay revealed that the parental 89.6 P and re-isolated viruses from unvaccinated 89.6 P-infected monkeys had quite an abundant and similar heterogeneous quasispecies population. In contrast, the viruses isolated from the vaccinated monkeys had different and fewer quasispecies indicating a selective immune pressure in the vaccinated monkeys. The in vitro replication of the viruses isolated from the vaccinated monkeys in human and macaque peripheral blood mononucular cells (PBMCs) as well as in established cell lines such as M8166 and HSC-F cells, were slow and delayed when compared to the parental 89.6 P and re-isolated viruses from unvaccinated 89.6 P-infected monkeys. Further comparison revealed that in HSC-F cells the viruses from vaccinated monkeys again showed delayed and weak CD4(+) cell down-modulation as well as having little or no effect on cell growth or cell viability on HSC-F cells and monkey PBMC. Thus we noticed that these re-isolated 89.6 P viruses from the vaccinated monkeys had changed or had been selected for low pathogenic viruses in the monkeys. This suggests that though the vaccination did not completely prevent the replication of the challenge virus in the monkeys it did contain the challenge virus by suppressing the pathogenic variants. This further enhances the prospects of this nef-deleted SHIV as the bases for effective anti-HIV vaccine candidates.
Similar articles
-
Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.Virology. 1999 Dec 20;265(2):252-63. doi: 10.1006/viro.1999.0049. Virology. 1999. PMID: 10600597
-
Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques.Virology. 1998 Sep 1;248(2):275-83. doi: 10.1006/viro.1998.9300. Virology. 1998. PMID: 9721236
-
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.J Virol. 2004 Jul;78(14):7490-7. doi: 10.1128/JVI.78.14.7490-7497.2004. J Virol. 2004. PMID: 15220422 Free PMC article.
-
A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.Microbiol Immunol. 1998;42(4):245-51. doi: 10.1111/j.1348-0421.1998.tb02279.x. Microbiol Immunol. 1998. PMID: 9623910 Review.
-
Candidate vaccines protect macaques against primate immunodeficiency viruses.AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S265-70. AIDS Res Hum Retroviruses. 1998. PMID: 9814954 Review.
Cited by
-
Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.Virology. 2009 Sep 30;392(2):260-70. doi: 10.1016/j.virol.2009.06.052. Epub 2009 Aug 3. Virology. 2009. PMID: 19647847 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials